---
document_datetime: 2026-01-20 10:15:33
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tocilizumab-stada-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tocilizumab-stada-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.513056
conversion_datetime: 2026-01-20 20:29:05.731324
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tocilizumab STADA

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | This was an application for a group of | 15/01/2026                          |                                          | SmPC, Annex                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000320498   | variations. A.2 Change in the(invented)name of the medicinal product-A.2.a)for Centrally Authorisedproducts-Accepted B.II.b.2.cReplacement or addition of a manufacturerresponsibleforimportation and/or batch release-B.I1.b.2.c.1 Not includingbatchcontrol/testing-Accepted B.II.b.1 Replacement or addition of a manufacturingsiteforpartor all of the manufacturing process of the finished product - B.11.b.1.a Secondary packaging site - Accepted B.I1.b.1 Replacement or addition of a manufacturingsiteforpartor all of the manufacturing process of the finished product - B.1I1.b.1.a Secondary packaging   | II, Labelling and PL   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | packaging site, manufacturer responsible for batchrelease,site wherebatch control takes place,or supplier of a startingmaterial, reagent orexcipient(when mentioned in the dossier)*- Accepted A.ADMINISTRATIVECHANGES-A.7 Deletionofmanufacturingsitesfor anactive substance, intermediate or finished product, packaging site,manufacturerresponsiblefor batchrelease,site wherebatchcontrol takes place,orsupplierofastartingmaterial, reagent or excipient (when mentioned in the dossier)*-Accepted A.ADMINISTRATIVECHANGES-A.7 Deletion ofmanufacturingsitesfor an active substance, intermediate or finished product, packaging site, manufacturer responsible for batchrelease,sitewherebatchcontroltakes place,orsupplierof astartingmaterial, reagent or excipient(when mentioned in the   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000314438 | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product-B.1I.b.5.f Addition or replacementof anin-processtest as aresult of a safety or quality issue - Accepted B.II.d.2 Change in test procedure for the finishedproduct-B.II.d.2.d Otherchanges                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 10/12/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                                         | toa testprocedure(includingreplacement or addition) - Accepted                                                                  |            |            |                        |             |
|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------|
| Marketing Authorisation Transfer - H / EMA/T/0000295813 | - Transfer of a marketing authorisation - transferofmarketingauthorizationfrom Biogen Netherlands B.V. to STADA Arzneimittel AG | 23/09/2025 | 09/10/2025 | SmPC, Labelling and PL |             |
| PSUR/EMA/PSUR/0000288251                                |                                                                                                                                 |            |            |                        | Maintenance |